Pfizer (PFE) Looks to Remove 'Black Box' Warning from Chantix

Pfizer (NYSE: PFE) will request that U.S. regulators remove a black box warning from its anti-smoking medication, Chantix.

According to reports Wednesday, the U.S. FDA recently updated labeling on Chantix which includes data from a number of recent studies that found little to no evidence of psychiatric problems or suicidal tendencies in patients taking the tablet.

The FDA will convene a panel in October to review Chantix's risks at the request of Pfizer.

You May Also Be Interested In

• Pfizer Declares Second-Quarter 2024 Dividend
• Acrivon Therapeutics (ACRV) Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
• Threshold to make it into the Top 100 biggest global companies is now at $141B - report